La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Siemens Energy a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Siemens Energy..

Siemens Energy (OTC:SMEGF) Azioni, Catena delle Opzioni

Siemens Energy manufactures a wide range of equipment used to generate and transmit energy. The group is a product of the spinout from Siemens AG in 2020, consisting of the power and gas segment and Siemens Gamesa, although its operations go back over 150 years. Approximately one sixth of global electricity generation is based on its technology.

Siemens Energy AG

Morgan Stanley analyst Meta Marshall maintains Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) with a Equal-Weight and raises the price target from $40 to $62.

News

Price Target

Analyst Ratings

PSTG

Morgan Stanley Maintains Equal-Weight on Pure Storage, Raises Price Target to $62

Jones Trading analyst Soumit Roy initiates coverage on ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy rating and announces Price Target of $40.

Initiation

AVBP

Jones Trading Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $40

Morgan Stanley analyst Meta Marshall maintains NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) with a Equal-Weight and raises the price target from $84 to $106.

NTAP

Morgan Stanley Maintains Equal-Weight on NetApp, Raises Price Target to $106

Basel Medical Group Ltd (NASDAQ:<a href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>), today announced that its subsidiary has been awarded a significant contract worth S$375 million by Pancare Technology International (HK) Limited to supply essential healthcare products in Asia-Pacific over the next five years until October 31, 2029. This milestone underscores the Company's commitment to delivering high-quality medical solutions and strengthening its global presence in the healthcare sector.
As part of the Company's strategic vision, the Company will be accelerating the integration of AI-powered technologies into its healthcare supply chain operations. This initiative aims to enhance efficiency, optimize logistics, and to ensure the timely delivery of critical medical products to healthcare providers across Asia-Pacific and beyond.

Contracts

BMGL

Basel Medical Group Subsidiary Bags S$375M Contract From Pancare Technology International To Supply Essential Healthcare Products In Asia-Pacific Until October 31, 2029

Morgan Stanley analyst Meta Marshall maintains Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) with a Overweight and raises the price target from $75 to $90.

NTNX

Morgan Stanley Maintains Overweight on Nutanix, Raises Price Target to $90

Morgan Stanley analyst Meta Marshall maintains Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) with a Equal-Weight and raises the price target from $14 to $22.

Morgan Stanley Maintains Equal-Weight on Hewlett Packard, Raises Price Target to $22

Jefferies analyst Julien Dumoulin-Smith upgrades Alliant Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>) from Hold to Buy and raises the price target from $70 to $71.

Upgrades

Jefferies Upgrades Alliant Energy to Buy, Raises Price Target to $71

As <a href="https://jaguarhealth.gcs-web.com/news-releases/news-release-details/proof-concept-results-show-crofelemer-reduced-total-parenteral">announced</a>, initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient with intestinal failure by up to 27%; per the IIT protocol, patient was taken off crofelemer after 12 weeks of treatment for a period of 30 days, but was restarted on daily crofelemer treatment after just 8 days, as patient's symptoms were worsening
Additional POC IIT results expected throughout 2025 for MVID; results from company's MVID Phase 2 study expected with completion of treatment in H2 2026
Ground-breaking results in single-digit number of MVID patients could potentially lead to expedited approval in the EU through <a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines">PRIME</a> and to <a href="https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy">Breakthrough Therapy</a> designation in the US
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / May 20, 2025 / <a href="https://pr.report/als3">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/als5">Napo Pharmaceuticals, Inc.</a> (Napo) and <a href="https://pr.report/als6">Napo Therapeutics S.p.A.</a> today announced that the first patient has been randomized in Napo's randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety and efficacy of the novel crofelemer oral powder for solution formulation in pediatric patients with intestinal failure due to the ultrarare disease MVID.
Patients with MVID suffer from devastating diarrhea and dehydration caused by this debilitating, lifelong condition. These pediatric patients often require lifelong and life-sustaining total parenteral nutrition (TPN) with additional supplemental intravenous (IV) fluids, termed total parenteral support, which is the standard of care for MVID, for up to 7 days a week greater than 50% of the time each day to provide adequate nutrient and electrolyte support. While crucial for MVID patients, TPN carries a significant risk of morbidity and mortality due to infections, metabolic complications, liver and/or kidney disease, and a risk of neurodevelopmental delay. There are currently no approved drug treatments for MVID.
Based on the initial proof-of-concept findings presented last month at the 11th Annual ELITE PED-GI Congress, crofelemer's novel antisecretory mechanism of action appears to have the potential to provide a novel therapeutic option to modify the disease progression associated with intestinal failure due to MVID in pediatric patients, as evidenced by the reductions in total parenteral support and potential to improve the quality of life of MVID patients.

JAGX

Jaguar Health Says First Patient Randomized In Napo's Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of Crofelemer In Pediatric Patients With MVID

Morgan Stanley analyst Kristine Liwag maintains RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) with a Overweight and raises the price target from $390 to $415.

Morgan Stanley Maintains Overweight on RBC Bearings, Raises Price Target to $415

INMD

InMode Announces Health Canada Certification Of IgniteRF Platform With New QuantumRF Tech

General

PTPI

Petros Pharmaceuticals Partners With Innolitics To Integrate Its Capabilities In The Development Of a SaaS Platform

Morgan Stanley analyst Betsy Graseck maintains JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Equal-Weight and raises the price target from $235 to $236.

Morgan Stanley Maintains Equal-Weight on JPMorgan Chase, Raises Price Target to $236

Jefferies analyst Dushyant Ailani maintains Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) with a Hold and lowers the price target from $1.7 to $0.9.

PLUG

Jefferies Maintains Hold on Plug Power, Lowers Price Target to $0.9

SatixFy Communications Ltd. Ordinary Share

SATX

SatixFy And MDA To Amend Merger Agreement Increasing Consideration To $3.00/Share, Valuing Company At $280M; No Other Acquisition Proposals To Be Considered And Board's Merger Support Maintained

Hovnanian Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOV#NYSE">HOV</a>) sees Q3 sales of $750.000 million-$850.000 million vs $742.50 million analyst estimate.

Guidance

Hovnanian Enterprises Sees Q3 Sales $750.000M-$850.000M vs $742.50M Est

U.S. spot Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">exchange-traded funds</a> recorded $667.44 million in net inflows on May 19, marking the fourth consecutive day of positive momentum.
Meanwhile, Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) ETFs also saw modest gains, with $13.66 million in net inflows and no redemptions across all nine listed products, <a href="https://sosovalue.com/zh/assets/etf/us-btc-spot">according</a> to SoSoValue data.
The strong inflows follow a broader institutional trend, backed by Standard Chartered's note on Tuesday, which suggests Bitcoin is gaining traction among a more diverse set of buyers despite some near-term headwinds.
While the SEC's Q1 13F filings showed a slight pullback in direct Bitcoin ETF exposure, driven by Wisconsin's pension fund liquidating its holdings in BlackRock's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) ETF, indirect exposure via Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) is reportedly increasing.
Sovereign wealth entities in Norway, Switzerland, and South Korea significantly boosted their MSTR positions, with Saudi Arabia also opening a new stake, a sign of growing institutional appetite for BTC proxies.
Also Read: <a href="https://www.benzinga.com/markets/25/05/45510166/el-salvadors-bitcoin-holdings-show-357-million-in-unrealized-profit-as-bitcoin-closes-at-record-high">El Salvador&#8217;s Bitcoin Holdings Show $357 Million In Unrealized Profit As Bitcoin Closes At Record Highs</a>
Standard Chartered reiterated its projection that Bitcoin could reach $500,000 before the end of Donald Trump's term ends, driven by rebalancing from underweight positions and declining volatility.
On May 19, the bulk of Bitcoin ETF inflows were concentrated in BlackRock's IBIT product, which added $305.92 million in new capital. 
Fidelity's (CBOE: FBTC) followed with $188 million, while Ark's (CBOE: ARKB) saw $155 million in inflows.
Ethereum ETF gains were more evenly distributed, with BlackRock's product leading at $13.6 million.
 The total asset value of U.S. Bitcoin ETFs now stands at $124.9 billion, compared to $8.7 billion for Ethereum ETFs.
Read Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45501880/jamie-dimon-opens-jpmorgan-to-bitcoin-access-despite-longstanding-criticism">Jamie Dimon Opens JPMorgan To Bitcoin Access Despite Longstanding Criticism</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

IBIT

MSTR

Bitcoin To Hit $500,000 By 2028, Standard Chartered Says, As ETFs Buy $667M On Monday

The Magnificent Seven – minus Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which is due to report earnings this week – delivered a stunning earnings beat in the first quarter of 2025, surpassing timid Street expectations and sending a clear message: the foundations of <a href="https://www.benzinga.com/tech">Big Tech's dominance remain firm.</a>
The six tech giants that have reported so far delivered an average EPS growth of 28% year over year — nearly three times the 9% pace seen across the rest of the S&amp;P 500.
They didn't just grow, they blew past expectations. Consensus estimates were exceeded by 16%, marking the most significant earnings surprise since the second quarter of 2021, when the group beat forecasts by 27%.
<h3 class="wp-block-heading">Big Tech Just Delivered Its Best Quarter In Four Years</h3>
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) were standouts. Alphabet delivered 48.7% EPS growth and beat expectations by nearly 39%. Amazon posted a 62.2% earnings jump, crushing its EPS estimate by over 16%.
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) followed with 36.5% growth, while Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) delivered 17.7%. Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) showed more modest growth of 7.8% but still edged out its target.
The laggard was Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), whose EPS fell 40% year-over-year, missing the mark by over 34%. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td></td>
<td>Reported EPS (Past Quarter)</td>
<td>YoY % growth</td>
<td>Expected EPS</td>
<td>Surprise (%)</td>
</tr>
<tr>
<td>Apple Inc.</td>
<td>$1.65</td>
<td>+7.8%</td>
<td>$1.627</td>
<td>1.4%</td>
</tr>
<tr>
<td>Microsoft Corp.</td>
<td>$3.46</td>
<td>+17.7%</td>
<td>$3.22</td>
<td>7.4%</td>
</tr>
<tr>
<td>Amazon.com Inc.</td>
<td>$1.59</td>
<td>+62.2%</td>
<td>$1.36</td>
<td>16.4%</td>
</tr>
<tr>
<td>Meta Platforms Inc.</td>
<td>$6.43</td>
<td>+36.5%</td>
<td>$5.2</td>
<td>22.8%</td>
</tr>
<tr>
<td>Alphabet Inc.</td>
<td>$2.81</td>
<td>+48.7%</td>
<td>$2.02</td>
<td>38.8%</td>
</tr>
<tr>
<td>Tesla Inc.</td>
<td>$0.27</td>
<td>-40%</td>
<td>$0.41</td>
<td>-34.1%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">MAGS ETF Rebounds, But Remains Underwater in 2025</h3>
The Roundhill Magnificent Seven ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NYSE">MAGS</a>), a tracker of these tech titans, has surged 34% from its April 7 lows, outpacing the SPDR S&amp;P 500 ETF Trust's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) 23% gain and Invesco QQQ Trust's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) 29% rally over the same period.
However, MAGS ETF remains 5% lower year-to-date. According to Dave Mazza, CEO at Roundhill Investments, this year&#8217;s drawdown reflected "increasing skepticism around valuations, sector concentration, and the growing impact of global trade disruptions." 
"These companies aren't speculative bets on future adoption," the expert noted. "They are the infrastructure of the real economy and, in some cases, staples within global consumers' lives."
Unlike previous cycles of concentrated market leadership, such as the Dot-Com boom, today&#8217;s leaders are not speculative growth stories but entrenched players in AI, cloud and automation.
Mazza highlighted that institutional flows into MAGS "remain relatively resilient," indicating long-term conviction hasn&#8217;t fully eroded.
All Eyes On Nvidia: The Final Piece Of The Puzzle
All eyes now turn to Nvidia, set to report earnings on May 28. 
Analysts expect EPS of $0.88, up 43% from the same quarter last year. Revenue estimates stand at $43.2 billion, which would represent a staggering 66% year-over-year increase. 
If those numbers hold, Nvidia could reinforce the Magnificent Seven's bullish narrative — and potentially lift the elite group of tech stocks into positive territory for the year.
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45513498/us-stock-futures-dip-after-sp-500s-six-day-streak-quick-recoveries-tend-to-see-stocks-rally-more-over-the-next-3-12-months-says-expert-citing-historical-data">US Stocks Likely To Open Lower After S&amp;P 500&#8217;s Six-Day Streak: &#8216;Quick Recoveries Tend To See Stocks Rally More Over The Next 3-12 Months,&#8217; Says Expert </a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Large Cap

Specialty ETFs

Tech

ETFs

AAPL

AMZN

GOOGL

MAGS

MSFT

NVDA

TSLA

Magnificent 7 Stun The Street With Best Earnings Beat Since 2021

Hovnanian Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOV#NYSE">HOV</a>) reported quarterly earnings of $2.43 per share which missed the analyst consensus estimate of $2.45 by 0.82 percent. This is a 63.51 percent decrease over earnings of $6.66 per share from the same period last year. The company reported quarterly sales of $686.47 million which missed the analyst consensus estimate of $733.20 million by 6.37 percent. This is a 3.09 percent decrease over sales of $708.38 million the same period last year.

Earnings

Earnings Misses

Hovnanian Enterprises Q2 GAAP EPS $2.43 Misses $2.45 Estimate, Sales $686.47M Miss $733.20M Estimate

Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Equal-Weight and raises the price target from $20 to $24.

ACAD

Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $24

Jefferies analyst Blayne Curtis downgrades Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) from Buy to Hold and lowers the price target from $135 to $110.

Comments

Siemens Energy

Siemens Energy (SMEGF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO